Federal Register / Vol. 80, No. 54 / Friday, March 20, 2015 / Notices 15035 

business information identified as 

directed above will be made publicly 

available in redacted form. 

An electronic copy of this document 

is available at http://

www.regulations.gov for easy reference. 

If you wish to personally inspect the 

comments and materials received, these 

materials will be available for public 

inspection by appointment. To arrange 

a viewing, please see the FOR FURTHER

INFORMATION CONTACT paragraph above. 

Legal Authority and Background 

Section 306 of the Controlled 

Substances Act (CSA), 21 U.S.C. 826, 

requires that the Attorney General 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

each year. This responsibility has been 

delegated to the Administrator of the 

Drug Enforcement Administration 

(DEA). 28 CFR 0.100. 

The DEA established the 2015 

aggregate production quotas for 

substances in schedules I and II on 

September 8, 2014 (79 FR 53216). 

Subsequently, on December 19, 2014, 

DEA published in the Federal Register 

a notice of intent to temporarily place 3 

synthetic cannabinoids: N-(1-amino-3- 

methyl-1-oxobutan-2-yl)-1- 

(cyclohexylmethyl)-1H-indazole-3- 

carboxamide (AB-CHMINACA), N-(1- 

amino-3-methyl-1-oxobutan-2-yl)-1- 

pentyl-1H-indazole-3-carboxamide (ABPINACA), and [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1- 

yl)methanone (THJ-2201) into schedule 

I of the CSA (79 FR 75767). On January 

30, 2015, the DEA published in the 

Federal Register a final order to 

temporarily place these three synthetic 

cannabinoids in schedule I of the CSA 

(80 FR 5042), making all regulatory 

controls pertaining to schedule I 

controlled substances applicable to the 

manufacture of these three synthetic 

cannabinoids, including the 

requirement to establish an aggregate 

production quota pursuant to 21 U.S.C. 

826 and 21 CFR part 1303. 

AB-CHMINACA, AB-PINACA, and 

THJ-2201 were non-controlled 

substances when the aggregate 

production quotas for schedule I and II 

substances were established. Therefore 

no aggregate production quotas for ABCHMINACA, AB-PINACA, and THJ2201 were established at that time. 

In determining the 2015 aggregate 

production quotas of these three 

synthetic cannabinoids, the 

Administrator considered the following 

factors in accordance with 21 U.S.C. 

826(a) and 21 CFR 1303.11(b): (1) Total 

net disposal of the class by all 

manufacturers during the current and 2 

preceding years; (2) trends in the 

national rate of net disposal of the class; 

(3) total estimated inventories of the 

basic class and of all substances 

manufactured from the class, and trends 

in inventory accumulation; (4) projected 

demand for each class as indicated by 

procurement quotas requested pursuant 

to 21 CFR 1303.12; and (5) other factors 

affecting medical, scientific, research, 

and industrial needs of the United 

States and lawful export requirements, 

as the Administrator finds relevant. 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

The Administrator, therefore, 

proposes that the annual 2015 aggregate 

production quotas for the following 

temporarily controlled schedule I 

controlled substances, expressed in 

grams of anhydrous acid or base, be 

established as follows: 

Basic class—schedule I 

Proposed 

2015 quota 

(g) 

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) .................................... 15 

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) .............................................................. 15 

[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) ...................................................................................... 15 

Dated: March 12, 2015. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2015–06456 Filed 3–19–15; 8:45 am] 

BILLING CODE 4410–09–P 

MORRIS K. UDALL AND STEWART L. 

UDALL FOUNDATION 

Sunshine Act Meetings 

TIME AND DATE: 9:00 a.m. to 4:00 p.m., 

Thursday, April 16, 2015. 

PLACE: The offices of the Morris K. 

Udall and Stewart L. Udall Foundation, 

130 South Scott Avenue, Tucson, AZ 

85701. 

STATUS: This meeting of the Board of 

Trustees will be open to the public. 

MATTERS TO BE CONSIDERED: (1) Chair’s 

Remarks; (2) Executive Director’s 

Remarks; (3) Overview of Trustee 

Responsibilities; (4) Board Officers & 

Committee Elections; (5) Consent 

Agenda Approval, including program 

reports of the Education Programs, U.S. 

Institute for Environmental Conflict 

Resolution, and Udall Center for Studies 

in Public Policy/Native Nations Institute 

for Leadership, Management, and 

Policy/Udall Archives, and resolutions 

related to the Operating Procedures of 

the Board of Trustees and the Parks in 

Focus Fund, Inc. (6) Financial and 

Internal Controls Update; (7) Ethics 

Briefing; (8) Program Panel & 

Discussion; and (9) Appropriations 

Update. 

CONTACT PERSON FOR MORE INFORMATION: 

Philip J. Lemanski, Executive Director, 

130 South Scott Avenue, Tucson, AZ 

85701, (520) 901–8500. 

Dated: March 16, 2015. 

Philip J. Lemanski, 

Executive Director, Morris K. Udall and 

Stewart L. Udall Foundation, and Federal 

Register Liaison Officer. 

[FR Doc. 2015–06556 Filed 3–18–15; 4:15 pm] 

BILLING CODE 6820–FN–P 

NUCLEAR REGULATORY 

COMMISSION 

[NRC–2015–0001] 

Sunshine Act Meetings 

DATES: March 23, 30, April 6, 13, 20, 27, 

2015. 

PLACE: Commissioners’ Conference 

Room, 11555 Rockville Pike, Rockville, 

Maryland. 

STATUS: Public and Closed. 

Week of March 23, 2015—Tentative 

Thursday, March 26, 2015 

9:30 a.m. Briefing on Security Issues 

(Closed—Ex. 1) 

1:30 p.m. Briefing on Security Issues 

(Closed—Ex. 1) 

Friday, March 27, 2015 

9:30 a.m. Briefing on Threat 

Environment Assessment (Closed— 

Ex. 1) 

mstockstill on DSK4VPTVN1PROD with NOTICES